- Welcome
- What is a Clinical Trial?
- Participation Benefits
- Types of Clinical Trials
- Phases of a Clinical Trial
- Participant Protection
- Eligibility
- Frequently Asked Questions
- Resources
- Open Oncology Clinical Trials
- Clinical Trials at Other Facilitites
Summary of Open Oncology Protocols
Select Oncology Protocol Site:
Protocol: Bone Mets - C70604
Title
A Randomized Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
A Randomized Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Treatment
Eligibility
Histologic documentation of prostate or breast adenocarcinoma or multiple myeloma. At least one bone met by radiographic imaging. No prior IV bisphosphonate treatment. No prior radiopharmaceuticals. At least 4 weeks from completion of prior radiation ther
Histologic documentation of prostate or breast adenocarcinoma or multiple myeloma. At least one bone met by radiographic imaging. No prior IV bisphosphonate treatment. No prior radiopharmaceuticals. At least 4 weeks from completion of prior radiation ther
Protocol: Bone Mets - SWOG S0702
Title
A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
Treatment
Eligibility
Bone mets from multiple myeloma, solid tumor, or other malignancy where bisphosphanate is indicated. Planned treatment with zoledronic acid. Less than or equal to 3 doses IV ibandronate, pamidronate, or zoledronic acid in past 3 years for osteopenia or o
Bone mets from multiple myeloma, solid tumor, or other malignancy where bisphosphanate is indicated. Planned treatment with zoledronic acid. Less than or equal to 3 doses IV ibandronate, pamidronate, or zoledronic acid in past 3 years for osteopenia or o
Protocol: Brain - RTOG R0825
Title
Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Treatment
Eligibility
Must have newly diagnosed, histo confirmed GBM or gliosarcoma (WHO grade IV) confirmed by central pathology office. Must have supratentorial component. Must have preop and postop MRI. Labs to be WNL. No mets detected below the tentorium or beyond the cran
Must have newly diagnosed, histo confirmed GBM or gliosarcoma (WHO grade IV) confirmed by central pathology office. Must have supratentorial component. Must have preop and postop MRI. Labs to be WNL. No mets detected below the tentorium or beyond the cran
Protocol: Breast - ECOG E5103
Title
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
Treatment
Eligibility
Histologically confirmed adenocarcinoma of the breast at significant risk of distant recurrence based on at least one of the following: Involvement of 1 lymph node on routine histologic exam; ER negative >/= 1 cm; ER+ tumor >/+ 5 cms regardless of recurre
Histologically confirmed adenocarcinoma of the breast at significant risk of distant recurrence based on at least one of the following: Involvement of 1 lymph node on routine histologic exam; ER negative >/= 1 cm; ER+ tumor >/+ 5 cms regardless of recurre
Protocol: Breast - NSABP B-39 /
Title
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
Treatment
Eligibility
Stage 0, 1, or 2 breast cancer. If stage 2, tumor size must be <3cm. Clear margins. No more than 3 histological positive axillary nodes. Women who are >50 with DCIS only, or over 50 with invasive, node neg and hormone positive are not eligible.
Stage 0, 1, or 2 breast cancer. If stage 2, tumor size must be <3cm. Clear margins. No more than 3 histological positive axillary nodes. Women who are >50 with DCIS only, or over 50 with invasive, node neg and hormone positive are not eligible.
Protocol: Breast - OHSU 4318
Title
A Phase II Open-Label Study of Sorafenib Plus Fulvestrant as Salvage Therapy For Hormone Receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment
A Phase II Open-Label Study of Sorafenib Plus Fulvestrant as Salvage Therapy For Hormone Receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment
Treatment
Eligibility
Incurable locally advanced or metastatic breast cancer with measurable or evaluable disease. Subjects with bone only mets that can be imaged with bone scan and MRI or bone scan and plain x-ray are eligible. Must be hormone receptor positive defined as >=1
Incurable locally advanced or metastatic breast cancer with measurable or evaluable disease. Subjects with bone only mets that can be imaged with bone scan and MRI or bone scan and plain x-ray are eligible. Must be hormone receptor positive defined as >=1
Protocol: Breast - PACCT1
Title
Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy vs Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)
Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy vs Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial)
Treatment
Eligibility
ER Positive and/or PR Positive. Axillary Node Negative. Candidate for adjuvant cytotoxic therapy in addition to hormonal therapy.
ER Positive and/or PR Positive. Axillary Node Negative. Candidate for adjuvant cytotoxic therapy in addition to hormonal therapy.
Protocol: Breast - S0715
Title
Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane Induced Neuropathy, Phase III
Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane Induced Neuropathy, Phase III
Treatment
Eligibility
Protocol: Breast - SWOG S0230
Title
Phase III Trial of LHRH Analog Administration during Chemotherapy to Reduce Ovarian Failure following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Phase III Trial of LHRH Analog Administration during Chemotherapy to Reduce Ovarian Failure following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Treatment
Eligibility
Operable stage I, II, or IIIA invasive breast cancer. Tumors must be ER & PR negative. Must be premenopausal. Must have modified radical mastectomy or local excision plus axillary lymph node dissection and/or sentinel node. Planned treatment must include
Operable stage I, II, or IIIA invasive breast cancer. Tumors must be ER & PR negative. Must be premenopausal. Must have modified radical mastectomy or local excision plus axillary lymph node dissection and/or sentinel node. Planned treatment must include
Protocol: Breast - SWOG S0622
Title
Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer
Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer
Treatment
Eligibility
Women or men with Stage IV breast cancer which is bone-predominant.
Women or men with Stage IV breast cancer which is bone-predominant.
Protocol: CML - CSTI571A24
Title
A Worldwide, Observational Registry collecting Longitudinal Data on the Management of Chronic Myelogenous Leukemia (CML) Patients (The WORLD CML Registry) in Routine Practice
A Worldwide, Observational Registry collecting Longitudinal Data on the Management of Chronic Myelogenous Leukemia (CML) Patients (The WORLD CML Registry) in Routine Practice
Treatment
Eligibility
Diagnosed with any phase ph+ or bcr-abl confirmed CML within 6 months of entry into the Registry. Provided informed consent.
Diagnosed with any phase ph+ or bcr-abl confirmed CML within 6 months of entry into the Registry. Provided informed consent.
Protocol: Colon - ECOG E5202
Title
Randomized Phase III Study Comparing FOLFOX Chemotherapy vs. FOLFOX Chemotherapy with Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
Randomized Phase III Study Comparing FOLFOX Chemotherapy vs. FOLFOX Chemotherapy with Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
Treatment
Eligibility
Enrollment suspended pending update to Consent
Histologically confirmed adenocarcinoma of the colon that is Stage II (T3,4 NO,MO). Distal extent of tumor must be >/= 12 cm from the anal verge as determined via endoscopy or surgery. Patients must have >/=
Enrollment suspended pending update to Consent
Histologically confirmed adenocarcinoma of the colon that is Stage II (T3,4 NO,MO). Distal extent of tumor must be >/= 12 cm from the anal verge as determined via endoscopy or surgery. Patients must have >/=
Protocol: Colon - OHSU 3753
Title
Phase II Study of Erlotinib (Tarceva) Alternating with Chemotherapy for Second-line Treatment of Metastatic Colorectal Cancer with Molecular Correlates for p53 Pathway
Phase II Study of Erlotinib (Tarceva) Alternating with Chemotherapy for Second-line Treatment of Metastatic Colorectal Cancer with Molecular Correlates for p53 Pathway
Treatment
Eligibility
Age 18-80. Biopsy proven unresectable metastatic adeno of the colon or rectum. Documented progression on prior first-line oxaliplatin-based or irinotecan-based regimen for metastatic colorectal cancer. Measurable disease of at least >1cm. First-line treat
Age 18-80. Biopsy proven unresectable metastatic adeno of the colon or rectum. Documented progression on prior first-line oxaliplatin-based or irinotecan-based regimen for metastatic colorectal cancer. Measurable disease of at least >1cm. First-line treat
Protocol: Esophageal - RTOG R0436
Title
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who are Treated Without Surgery
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer Who are Treated Without Surgery
Treatment
Eligibility
Histologically proven diagnosis, via endoscopy, of primary squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction within 6 weeks of registration. All disease must be encompassed in the radiotherapy field. Stage T1N1MO; T2-4,Any N, M
Histologically proven diagnosis, via endoscopy, of primary squamous cell or adenocarcinoma of the esophagus or gastroesophageal junction within 6 weeks of registration. All disease must be encompassed in the radiotherapy field. Stage T1N1MO; T2-4,Any N, M
Protocol: Head and Neck - ECOG E1305
Title
A Phase III Randomized Trial of Cisplatin and Docetaxel with or without Bevacizumab In Patients with Recurrent or Metastatic Head and Neck Cancer
A Phase III Randomized Trial of Cisplatin and Docetaxel with or without Bevacizumab In Patients with Recurrent or Metastatic Head and Neck Cancer
Treatment
Eligibility
Must have histological or cytologically confirmed Squamous cell (SCCHN) from any primary site. Must not have nasopharyngeal carcinoma of histologic types WHO 2 or 3 squamous that originated in the skin. Patients must have SCCHN that is either recurrent, i
Must have histological or cytologically confirmed Squamous cell (SCCHN) from any primary site. Must not have nasopharyngeal carcinoma of histologic types WHO 2 or 3 squamous that originated in the skin. Patients must have SCCHN that is either recurrent, i
Protocol: Lung - C30607
Title
Randomized, Phase III, Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
Randomized, Phase III, Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
Treatment
Eligibility
Histologic or cytologic stage IIIB or IV NSCLC. No brain mets or spinal cord compression. Patients must have received 4 cycles of platinum-based doublet therapy with or without bevacizumab. No evidence of disease progression. No prior adjuvant chemo for s
Histologic or cytologic stage IIIB or IV NSCLC. No brain mets or spinal cord compression. Patients must have received 4 cycles of platinum-based doublet therapy with or without bevacizumab. No evidence of disease progression. No prior adjuvant chemo for s
Protocol: Lung - ECOG E1505
Title
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
Treatment
Eligibility
Complete resection of Stage 1B (>4cm)- IIIA non-small cell lung cancer. Wedge resection or segmentectomy will not be accepted. Lymph node sampling is expected. Refer to protocol for specifics. Patients must be no less than 6 weeks and no more than 12 week
Complete resection of Stage 1B (>4cm)- IIIA non-small cell lung cancer. Wedge resection or segmentectomy will not be accepted. Lymph node sampling is expected. Refer to protocol for specifics. Patients must be no less than 6 weeks and no more than 12 week
Protocol: Lung - RTOG R0617
Title
A Randomized Phase III Comparison of Standard Dose (60Gy)Versus High Dose (74Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND 103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer
A Randomized Phase III Comparison of Standard Dose (60Gy)Versus High Dose (74Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND 103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer
Treatment
Eligibility
Histo or cyto NSCLC within 12 weeks of registration. Tumor cosidered unresectable or inoperable. Must be stage IIIA or IIIB with no distant mets. No supraclavicular or contralateral hilar disease. For additional eligibility criteria contact Clinical Resea
Histo or cyto NSCLC within 12 weeks of registration. Tumor cosidered unresectable or inoperable. Must be stage IIIA or IIIB with no distant mets. No supraclavicular or contralateral hilar disease. For additional eligibility criteria contact Clinical Resea
Protocol: Lung - S0819
Title
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer(NSCLC)
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer(NSCLC)
Treatment
Eligibility
Histo or Cyto proven newly diagnosed Stage IV Adeno, large cell, squamous, or unspecified NSCLC, or recurrent disease after prev surg/RT. Pt with controlled(min 2 months)brain mets after tx&no residual neurological dysfuntion off steroids are eligible. Me
Histo or Cyto proven newly diagnosed Stage IV Adeno, large cell, squamous, or unspecified NSCLC, or recurrent disease after prev surg/RT. Pt with controlled(min 2 months)brain mets after tx&no residual neurological dysfuntion off steroids are eligible. Me
Protocol: Lung - SWOG S0802
Title
A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)
A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)
Treatment
Eligibility
Histo/Cyto confirmed extensive stage small cell lung ca with progression or recurrence after receiving exactly one standard first-line platinum-containing regime. Measurable/non-measureable disease. Known brain mets ok only if pt has been treated and sta
Histo/Cyto confirmed extensive stage small cell lung ca with progression or recurrence after receiving exactly one standard first-line platinum-containing regime. Measurable/non-measureable disease. Known brain mets ok only if pt has been treated and sta
Protocol: Lung - SWOG S9925
Title
Lung Cancer Specimen Repository Protocol, Ancillary
Lung Cancer Specimen Repository Protocol, Ancillary
Treatment
Eligibility
Must be registered to a treatment protocol: S0536; S0424
Must be registered to a treatment protocol: S0536; S0424
Protocol: Lymphoma - SWOG 8947
Title
Central Lymphoma Serum Repository Protocol
Central Lymphoma Serum Repository Protocol
Treatment
Eligibility
Must be registered to a treatment protocol.
Must be registered to a treatment protocol.
Protocol: Lymphoma - SWOG 9245
Title
Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease
Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease
Treatment
Eligibility
Must be registered to a treatment protocol: 8410; 8503; 8508; 8516; 8736; 8809; 8907; 8954; 9125; 9240; 9320; 9349; 9432; 9501; 9703; S9704; 9800
Must be registered to a treatment protocol: 8410; 8503; 8508; 8516; 8736; 8809; 8907; 8954; 9125; 9240; 9320; 9349; 9432; 9501; 9703; S9704; 9800
Protocol: Melanoma - SWOG E1697
Title
Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2bNo, T3a-bNo, T4a-bNo, and T1-4, N1a,2a(microscopic) Melanoma
Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2bNo, T3a-bNo, T4a-bNo, and T1-4, N1a,2a(microscopic) Melanoma
Treatment
Eligibility
Melanoma of a cutaneous orgin. Stage T2bNo, T3a-bNo, T4a-bNo, and T1-4, N1a,2a,. Patients must complete all primary therapy (wide exicision with or without lymphadenectomy) and be randomized within 84 days of their wide excision. No prior chemotherapy, ra
Melanoma of a cutaneous orgin. Stage T2bNo, T3a-bNo, T4a-bNo, and T1-4, N1a,2a,. Patients must complete all primary therapy (wide exicision with or without lymphadenectomy) and be randomized within 84 days of their wide excision. No prior chemotherapy, ra
Protocol: Melanoma - SWOG S0826
Title
Phase II Study of SCH 727965 in Stage IV Melanoma
Phase II Study of SCH 727965 in Stage IV Melanoma
Treatment
Eligibility
Must have biopsy proven stage IV cutaneous/mucosal malignant melanoma. Ocular not eligible. Measurable/non measurable disease. Must have neg Brain CT/MRI within 42 days of reg. HX Brain Mets not eligible. Zubrod 0-1,18 yrs old or older.May have received u
Must have biopsy proven stage IV cutaneous/mucosal malignant melanoma. Ocular not eligible. Measurable/non measurable disease. Must have neg Brain CT/MRI within 42 days of reg. HX Brain Mets not eligible. Zubrod 0-1,18 yrs old or older.May have received u
Protocol: Pancreas - SWOG S0727
Title
A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460)vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients with Metastatic Pancreatic Cancer
A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460)vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients with Metastatic Pancreatic Cancer
Treatment
Eligibility
Histo or Cyto confirmed pancreatic adenoca:Stg IV unresectable. Macro residual disease not eligible. No sig acites. NO prior chemo, hormonal tx, imunotx, chemo/rt for advanced/locally advanced pan ca. No prior Gemcitibine for any reason. Prior surg ok if
Histo or Cyto confirmed pancreatic adenoca:Stg IV unresectable. Macro residual disease not eligible. No sig acites. NO prior chemo, hormonal tx, imunotx, chemo/rt for advanced/locally advanced pan ca. No prior Gemcitibine for any reason. Prior surg ok if
Protocol: Prostate - OHSU 2734
Title
A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer
A Randomized Phase II Study of Intermittent Chemotherapy or Intermittent Chemotherapy with Maintenance GM-CSF in Patients with Previously Untreated Metastatic Hormone Refractory Prostate Cancer
Treatment
Eligibility
Previously Untreated Metastatic Hormone Refractory Prostate Cancer
Previously Untreated Metastatic Hormone Refractory Prostate Cancer
Protocol: Prostate - RTOG R0534
Title
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (Spport) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (Spport) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
Treatment
Eligibility
Adenocarcinoma of the prostate treated primarily with radical prostatectomy, pathologically proven to be lymph node negative by pelvic lymphadenectomy (NO) or lymph node status pathologically unknown (undissected pelvic lymph nodes); Post radical prostate
Adenocarcinoma of the prostate treated primarily with radical prostatectomy, pathologically proven to be lymph node negative by pelvic lymphadenectomy (NO) or lymph node status pathologically unknown (undissected pelvic lymph nodes); Post radical prostate
Protocol: Renal - ECOG E2805
Title
Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Treatment
Eligibility
Patients with histological or cytological confirmed RCC T1B, T2, T3 and T4 with any N. Patients must have undergone full surgical resection - radical or partial nephrectomy by either open or laparoscopic technique, with clear margins. Positive regional LN
Patients with histological or cytological confirmed RCC T1B, T2, T3 and T4 with any N. Patients must have undergone full surgical resection - radical or partial nephrectomy by either open or laparoscopic technique, with clear margins. Positive regional LN
Protocol: Tissue Registry - OHSU 3082
Title
Oregon Colorectal Cancer Registry
Oregon Colorectal Cancer Registry
Treatment
Eligibility
Must be diagnosed with colorectal, endometrial, bladder or other HNPCC cancers
Must be diagnosed with colorectal, endometrial, bladder or other HNPCC cancers
Protocol: Tissue Registry - OHSU 4919
Title
Personalized Cancer Medicine Registry: A Registry of Patients with Molecularly Characterized Malignancies
Personalized Cancer Medicine Registry: A Registry of Patients with Molecularly Characterized Malignancies
Treatment
Eligibility
Histologically or cytologically confirmed diagnosis of cancer.
Histologically or cytologically confirmed diagnosis of cancer.
Last Updated: March 18, 2010